JP2019528077A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528077A5 JP2019528077A5 JP2019510951A JP2019510951A JP2019528077A5 JP 2019528077 A5 JP2019528077 A5 JP 2019528077A5 JP 2019510951 A JP2019510951 A JP 2019510951A JP 2019510951 A JP2019510951 A JP 2019510951A JP 2019528077 A5 JP2019528077 A5 JP 2019528077A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- host cell
- chimeric
- antigen
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 210000004027 cell Anatomy 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 230000027455 binding Effects 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 8
- 230000009870 specific binding Effects 0.000 claims 8
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims 7
- 230000015788 innate immune response Effects 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 7
- 230000006337 proteolytic cleavage Effects 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 210000002865 immune cell Anatomy 0.000 claims 6
- 108091006106 transcriptional activators Proteins 0.000 claims 6
- 239000000411 inducer Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000017854 proteolysis Effects 0.000 claims 5
- 102000005650 Notch Receptors Human genes 0.000 claims 4
- 108010070047 Notch Receptors Proteins 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108010077805 Bacterial Proteins Proteins 0.000 claims 1
- 108010058643 Fungal Proteins Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022057245A JP2022106714A (ja) | 2016-08-23 | 2022-03-30 | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378614P | 2016-08-23 | 2016-08-23 | |
| US62/378,614 | 2016-08-23 | ||
| PCT/US2017/048040 WO2018039247A1 (en) | 2016-08-23 | 2017-08-22 | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022057245A Division JP2022106714A (ja) | 2016-08-23 | 2022-03-30 | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528077A JP2019528077A (ja) | 2019-10-10 |
| JP2019528077A5 true JP2019528077A5 (enExample) | 2020-09-24 |
| JP7500195B2 JP7500195B2 (ja) | 2024-06-17 |
Family
ID=61245300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510951A Active JP7500195B2 (ja) | 2016-08-23 | 2017-08-22 | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
| JP2022057245A Ceased JP2022106714A (ja) | 2016-08-23 | 2022-03-30 | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022057245A Ceased JP2022106714A (ja) | 2016-08-23 | 2022-03-30 | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11401332B2 (enExample) |
| EP (1) | EP3504245A4 (enExample) |
| JP (2) | JP7500195B2 (enExample) |
| KR (2) | KR20190051956A (enExample) |
| CN (1) | CN109843929B (enExample) |
| AU (1) | AU2017316649A1 (enExample) |
| CA (1) | CA3034093A1 (enExample) |
| SG (2) | SG10201913583QA (enExample) |
| WO (1) | WO2018039247A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130280334A1 (en) | 2010-09-24 | 2013-10-24 | Massachusetts Institute Of Technology | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents |
| EP3258967A4 (en) | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| HK1250918A1 (zh) | 2015-04-06 | 2019-01-18 | Cytoimmune Therapeutics, Inc. | 用於胶质母细胞瘤的egfr导向的car疗法 |
| ES2964694T3 (es) * | 2016-09-15 | 2024-04-09 | Elicera Therapeutics Ab | Inmunoterapia de células T |
| US11020410B2 (en) | 2017-02-03 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| CN111406068A (zh) * | 2017-05-16 | 2020-07-10 | 约翰霍普金斯大学 | MANAbody及使用方法 |
| US11325957B2 (en) * | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
| AU2019233917A1 (en) * | 2018-03-16 | 2020-09-17 | Cytoimmune Therapeutics, Inc. | Bispecific antibody car cell immunotherapy |
| GB201804291D0 (en) * | 2018-03-16 | 2018-05-02 | Evox Therapeutics Ltd | Cell-mediated exosome delivery |
| US20190307885A1 (en) | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Self-assembled gels for controlled delivery of biologics and methods of making thereof |
| EP3773623A4 (en) * | 2018-04-06 | 2022-01-05 | The Regents of The University of California | TRANS ANTIGEN TARGETING IN HETEROGENIC CARCINOMA AND METHOD OF USING IT |
| EP3773633A4 (en) | 2018-04-06 | 2022-01-26 | The Regents of The University of California | METHODS OF TREATMENT OF GLIOBLASTOMA |
| AU2019249215A1 (en) | 2018-04-06 | 2020-10-22 | The Regents Of The University Of California | Methods of treating EGFRvIII expressing glioblastomas |
| KR20210008840A (ko) * | 2018-04-10 | 2021-01-25 | 스티흐팅 산퀸 불드포르지닝 | 키메라 노치 수용체 |
| WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| WO2020097395A1 (en) | 2018-11-08 | 2020-05-14 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| US12454562B2 (en) | 2018-12-06 | 2025-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatable cell surface receptors and related compositions and methods |
| CN113164578B (zh) * | 2019-01-03 | 2024-04-30 | 南京传奇生物科技有限公司 | 表达鞭毛蛋白多肽的经修饰的免疫细胞 |
| MX2022001711A (es) * | 2019-08-09 | 2022-05-10 | A2 Biotherapeutics Inc | Receptores en la superficie celular que responden a la perdida de heterocigosidad. |
| US20220348677A1 (en) * | 2019-09-24 | 2022-11-03 | The Regents Of The University Of California | Receptors with heterologous transmembrane domain |
| KR20220087454A (ko) * | 2019-09-24 | 2022-06-24 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 힌지 도메인을 갖는 노치 수용체 |
| US20220356225A1 (en) * | 2019-09-24 | 2022-11-10 | The Regents Of The University Of California | Notch receptors with zinc finger-containing transcriptional effector |
| CN114729025A (zh) * | 2019-09-24 | 2022-07-08 | 加利福尼亚大学董事会 | 用于配体依赖性转录调控的新型受体 |
| CN110716044B (zh) * | 2019-10-23 | 2023-04-18 | 郑州大学 | 一种用于食管鳞癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法 |
| US12195723B2 (en) | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| CN110970090B (zh) * | 2019-11-18 | 2021-06-29 | 华中科技大学 | 一种用于判断待处理多肽与阳性数据集肽段相似度的方法 |
| EP4072596A4 (en) * | 2019-12-12 | 2024-03-06 | Senti Biosciences, Inc. | METHOD AND COMPOSITIONS FOR REGULATED REINFORCEMENT OF CELLS |
| CN115151644B (zh) * | 2019-12-27 | 2024-06-21 | 国立大学法人神户大学 | 癌基因治疗药 |
| US20230226213A1 (en) * | 2020-06-18 | 2023-07-20 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating cells and cellular membranes |
| JP7634653B2 (ja) | 2020-08-20 | 2025-02-21 | エー２ バイオセラピューティクス， インコーポレイテッド | メソテリン陽性がんを治療するための組成物及び方法 |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| US20240150755A1 (en) * | 2021-02-26 | 2024-05-09 | Salk Institute For Biological Studies | Modulating regulatory t cell function in autoimmune disease and cancer |
| EP4314038A4 (en) * | 2021-03-23 | 2025-01-29 | The Regents of the University of California | SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR PERSONALIZED ANTIGEN-INDUCED TRANSCRIPTION REGULATION |
| US20250288672A1 (en) * | 2021-03-24 | 2025-09-18 | Raymond Liu | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
| CN114045272B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用 |
| EP4416292A2 (en) | 2021-10-14 | 2024-08-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| CN114107253B (zh) * | 2021-12-17 | 2024-03-15 | 复旦大学附属华山医院 | 一种利用工程细胞进行基因编辑的系统及方法 |
| CN114736308B (zh) * | 2022-03-15 | 2022-12-27 | 四川宜美康科技有限公司 | 球虫抗原肽/il5的融合蛋白基因工程菌的制备及用途 |
| CN117510615B (zh) * | 2023-01-31 | 2025-01-07 | 上海恩凯细胞技术有限公司 | SynNotch受体及其用途 |
| WO2025076422A1 (en) * | 2023-10-05 | 2025-04-10 | The Regents Of The University Of California | Regulated expression of card11-pik3r3 fusion protein |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
| GB0112818D0 (en) | 2001-05-25 | 2001-07-18 | Lorantis Ltd | Conjugate |
| GB0220658D0 (en) | 2002-09-05 | 2002-10-16 | Lorantis Ltd | Immunotherapy |
| PL2066694T3 (pl) | 2006-09-29 | 2016-04-29 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworu |
| EP2195658A2 (en) | 2007-09-28 | 2010-06-16 | Royal College of Surgeons in Ireland | A method of assessing colorectal cancer status in an individual |
| MX2011000233A (es) | 2008-07-08 | 2011-05-19 | Oncomed Pharm Inc | Agentes de union del receptor notch1 y metodos para su uso. |
| EP3072961A1 (en) | 2010-04-16 | 2016-09-28 | Children's Medical Center Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| CA2929087A1 (en) | 2013-10-31 | 2015-05-07 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| US9730935B2 (en) | 2013-12-13 | 2017-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting a non-canonical notch signaling pathway for cancer treatment |
| JP6560682B2 (ja) | 2014-01-08 | 2019-08-14 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 小細胞肺癌に対する標的療法 |
| EP3105335B1 (en) | 2014-02-14 | 2019-10-02 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| JP6665102B2 (ja) | 2014-02-21 | 2020-03-13 | セレクティスＣｅｌｌｅｃｔｉｓ | 制御性ｔ細胞をインサイチューで阻害するための方法 |
| WO2015130766A1 (en) * | 2014-02-25 | 2015-09-03 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
| EP3174546B1 (en) * | 2014-07-31 | 2019-10-30 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| DK4074735T3 (da) | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| JP2017529841A (ja) * | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| WO2016093243A1 (ja) | 2014-12-09 | 2016-06-16 | 北海道公立大学法人札幌医科大学 | 腫瘍抗原ペプチド |
| AU2016222887B2 (en) | 2015-02-24 | 2022-07-14 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| US11400116B2 (en) | 2016-05-06 | 2022-08-02 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
-
2017
- 2017-08-22 JP JP2019510951A patent/JP7500195B2/ja active Active
- 2017-08-22 WO PCT/US2017/048040 patent/WO2018039247A1/en not_active Ceased
- 2017-08-22 CN CN201780063755.8A patent/CN109843929B/zh active Active
- 2017-08-22 KR KR1020197005928A patent/KR20190051956A/ko not_active Ceased
- 2017-08-22 AU AU2017316649A patent/AU2017316649A1/en not_active Abandoned
- 2017-08-22 EP EP17844296.8A patent/EP3504245A4/en active Pending
- 2017-08-22 US US16/325,657 patent/US11401332B2/en active Active
- 2017-08-22 SG SG10201913583QA patent/SG10201913583QA/en unknown
- 2017-08-22 SG SG11201901528RA patent/SG11201901528RA/en unknown
- 2017-08-22 KR KR1020237006942A patent/KR102637610B1/ko active Active
- 2017-08-22 CA CA3034093A patent/CA3034093A1/en active Pending
-
2022
- 2022-03-30 JP JP2022057245A patent/JP2022106714A/ja not_active Ceased
- 2022-06-15 US US17/841,595 patent/US12358988B2/en active Active
-
2025
- 2025-06-10 US US19/234,169 patent/US20250304698A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528077A5 (enExample) | ||
| US20240294664A1 (en) | Chimeric antigen receptors, compositions, and methods | |
| JP2020503885A5 (enExample) | ||
| JP2019519227A5 (enExample) | ||
| IL275743A (en) | New bispecific format suitable for use in high-through-put screening | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2021019625A (ja) | 結合誘発型転写スイッチ及びその使用方法 | |
| JP2019514361A5 (enExample) | ||
| JP2017518037A5 (enExample) | ||
| JP2017522891A5 (enExample) | ||
| JP2020512820A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| JP2018528786A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| JP2018522564A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2015528003A5 (enExample) | ||
| JP2017537919A5 (enExample) | ||
| RU2019134273A (ru) | Конструкты индуктора презентации антигена опухоли и их использование | |
| JP2017501702A5 (enExample) | ||
| JPWO2020077257A5 (enExample) | ||
| JPWO2020104676A5 (enExample) | ||
| CN114763387B (zh) | 一种基于结构优化蛋白活性的三特异性抗体制备方法 | |
| JPWO2021163299A5 (enExample) |